Physician profile
Colin N Vanhook
NPI 1831484153
$1,195.37
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $165 · 2021: $102 · 2022: $110 · 2023: $247 · 2024: $193 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.04 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Jazz Pharmaceuticals INC. | $233.14 | 2022-2025 | Epidiolex |
| Ucb, INC. | $167.64 | 2019-2024 | Briviact |
| Sunovion Pharmaceuticals INC. | $117.85 | 2019-2020 | |
| Amgen INC. | $79.21 | 2019-2022 | |
| Sk Life Science, INC. | $63.86 | 2023-2025 | |
| Allergan, INC. | $36.02 | 2019-2020 | |
| Eisai INC. | $31.23 | 2021 | |
| Neurocrine Biosciences, INC. | $20.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.84 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.15 | 2020 | |
| Neurelis, INC. | $17.47 | 2020 | |
| Pfizer INC. | $17.24 | 2025 | |
| Acorda Therapeutics, INC | $16.61 | 2020 | |
| Zyla Life Sciences, INC. | $15.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Vanhook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.